Jasper Therapeutics, Inc.
No enriched coverage for $JSPR in the last 7 days.
No SEC Form 4 filings for $JSPR in the last 30 days.
See all $JSPR insider activity →Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 21, 2026, Jasper Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, base
Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.
Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
Recent JSPR coverage spans corporate actions, earnings and mergers & acquisitions.
Potential loss of Nasdaq listing could pressure share price and liquidity.
The print beat on losses, but the market is discounting execution risk and pipeline integration after the Kira acquisition and $132M financing.
The filing combines dilution/capital raise details with a major portfolio expansion via Kira, and reiterates near-term clinical milestones and cash position.
Financing plus post-acquisition pipeline milestones reduce near-term funding risk and set specific FDA interaction and trial timing catalysts.
This is a routine corporate governance disclosure with no new operating or financial guidance.
alphai scores every news story that mentions JSPR with an AI model for sentiment and relevance, and aggregates insider trades from Jasper Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 - Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 21, 2026, Jasper Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, base
2 min readJasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.
4 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders
6 min readJasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.
6 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07. Submission of Matters to a Vote of Security Holders . On July 31, 2026, Jasper Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 21,121,396 shares of the Company’s voting common sto
2 min readJasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined Nasdaq-listed company under ticker JSPR. The deal includes a $132M private placement and a $12M Mirador out-licensing payment on signing, funding operations through H2 2028. Pipeline includes KP-104, briquilimab, and KP-701 with upcoming clinical milestones.
5 min readJasper Therapeutics (NASDAQ:JSPR) closed a deal with Kira and completed a private placement of non-voting convertible preferred stock raising about $132 million gross. The company expects cash to fund operations through 2H 2028. Jasper out-licensed Kira’s KP-301 and KP-402 to Mirador for $12 million upfront plus milestones. JSPR shares rose 20.67% to $0.9250.
5 min readJasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 ea029822901ex2-1.htm AGREEMENT AND PLAN OF MERGER, DATED JULY 16, 2026, BY AND AMONG JASPER THERAPEUTICS, INC., KIRA HOLDCO INC. AND KIRA PHARMACEUTICALS Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: JASPER THERAPEUTICS, INC., a Delaware corporation; KIRA HOLDCO INC.,
6 min readJasper Therapeutics (NASDAQ: JSPR) announced that director Christian Nolet resigned from its Board of Directors and associated committees, effective May 15, 2026. The company stated that his resignation was not due to any disagreements regarding operations or policies. Concurrently, Svetlana Lucas, Ph.D. was appointed to the Board’s Audit Committee.
2 min readNEW YORK, Nov. 22, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, Inc. ( NASDAQ:DRVN ) and Jasper Therapeutics, Inc ( NASDAQ:JSPR ) on behalf of long-term ...
2 min read
